Abstract
Prostate cancer is the most frequently diagnosed cancer among men in the western world. The androgen receptor, a phosphoprotein, is suspected to be involved in all stages of the prostate cancer. Androgen receptor activity can be modulated by various kinases such as PKA, MAPK, AKT, and Src. Phosphorylation is an important post-translational modification and serves as a molecular on/off switch to regulate signaling. Disruptions of cellular phosphorylation are associated with various diseases such as cancer and kinases provide important drug targets. Here we present an analysis of the phosphoproteome in LNCaP human prostate cancer cells. The analytical strategy employed used proteomics based methodologies with a combination of detergent and chaotropic reagent during trypsin digestion followed by titanium dioxide enrichment of phosphopeptides. Over the course of multiple analyses by mass spectrometry we identified a total of 746 phosphorylation sites in 540 phosphopeptides corresponding to 116 phosphoproteins, of which 56 have not been previously reported. Phosphoproteins identified included transcription factors, co-regulators of the androgen receptor, and cancer-related proteins that include β-catenin, USP10, and histone deacetylase-2. The information of signaling pathways, motifs of phosphorylated peptides, biological processes, molecular functions, cellular components, and protein interactions from the identified phosphoproteins established a map of phosphoproteome and signaling pathways in LNCaP cells.
Introduction
Prostate cancer is the most common cancer in men and the most frequent cancer-related death after lung cancer in Europe and North America. A comprehensive understanding of the pathways and molecules that affect the heterogeneous progression of prostate cancer to an advanced terminal stage is required to identify mechanisms and therapeutic targets to improve the clinical management of the disease. Important pathways suspected to be involved in the progression of prostate cancer include the androgen receptor (AR) and various kinases such as PKA, MAPK, AKT, erbB2, and Src1–7.
Protein phosphorylation is the most widespread post-translational modification (PTM) in nature and occurs on at least one third of all proteins in mammalian cells8. Phosphorylation of proteins by a series of kinases with specific activities in different systems can regulate protein function, turnover, cellular localization and various biological processes such as signaling pathways by triggering a conformational change, subcellular location, generating binding sites for an interacting partners or altering its stability. Phosphorylation of nuclear receptors such as the AR and their coactivators alters their subsequent transcriptional activities. Changes in phosphorylation of AR may directly alter protein-protein interactions or indirectly alter interactions through changes in other PTMs, such as sumoylation and acetylation, or lead to changes in degradation, expression, and cellular localization of essential proteins. The disruption of phosphorylation events in a cell or tissue is associated with many diseases including cancers such as prostate cancer.
Development of global and quantitative methods for elucidating phosphorylation events is essential for biochemical analysis of cellular events that may be involved. Mass spectrometry (MS) based analysis is a powerful technology for proteomics and a method of choice for phosphorylation owing to its high sensitivity and ability to identify phosphorylation sites by MS/MS sequencing9, 10. Functional proteomics techniques coupled with MS have contributed to prostate cancer study through revealing the molecular mechanisms and biological processes by analyzing protein-protein, DNA or RNA interactions as well as PTMs. Examples include discovery of potential biomarkers for prostate cancer using SELDI11 and SILAC12, and identification of proteins that interact with AR by MudPIT13. Phosphorylation of a number of individual molecules have been identified and shown to have biological effect on important signaling pathways in prostate cancer14–19. To date, there are two phosphoproteome analysis using MS-based approach to identify phosphoproteins in prostate cancer cells20, 21. Here we identify phosphoproteins in LNCaP human prostate cancer cells with a combination of detergent and chaotropic reagent use during trypsin digestion to provide a global view of regulation of signaling pathways by phosphorylation and produce a reference for the phosphoproteome of a model of prostate cancer.
Results
To identify the phosphoproteome in a model of prostate cancer, we used the well-characterized LNCaP human prostate cancer cells. These cells can be maintained in vitro or grown in vivo as xenografts. LNCaP cells originated from a lymph node metastasis and express the AR and prostate-specific antigen (PSA), which is the clinical biomarker for prostate cancer. LNCaP cells are responsive to androgens and progress to the castration recurrent stage thereby mimicking several important aspects of the disease. The phosphoproteome strategy (Fig. 1) employed here successfully identified 540 phosphopeptides. Some of these phosphoproteins are known as cancer-related proteins and AR-interacting molecules. Creation of a map of phosphoproteome in LNCaP cells may aid in elucidating signaling pathways involved in molecular functions, biological processes, and cellular components.
Fig. 1. Outline of the experimental strategy for identification of phosphoproteome of LNCaP cells.
Flowchart of the experimental scheme of phosphoproteome analysis. NaDOC, sodium deoxycholate; TiO2, titanium dioxide; HPLC, high performance liquid chromatography.
Effect of sodium deoxycholate and urea on trypsin digestion for phosphopeptide preparation
The success of large-scale phosphoproteome analysis is dependent on efficient methods to extract and enrich for phosphopeptides from complex samples with minimal contamination by non-phosphorylated peptides. Chromatographic resins such as immobilized metal affinity chromatography (IMAC) and TiO2 can be applied for enrichment of phosphopeptides from a mixture of peptides. Different protocols for purification of phosphopeptides may result in varying efficiencies. Here we used TiO2 which is more stable than IMAC in detergents, salts and buffers that are frequently used in biological experiments22. NP-40 in Tris-HCl lysis buffer with proteases and phosphatase inhibitors was used based upon its use in successful analysis of the phosphoproteome of Jurkat cells10.
Protein digestion is critical step as it produces peptides from intact proteins for MS analysis. Chaotropes and some detergents can be added to improve denaturation of proteins for MS-based analyses. Enzyme digestion of proteins in solution with MS-compatible reagents improves the protein identification ratio by generating more diverse mixture of peptides. Conditions and various MS-compatible reagents have been reported and compared for enzyme digestion23, 24, but require optimization for maximum identification of proteins in a specific experiment.
Here we used both NaDOC and urea during enzyme digestion to increase the efficiency of identification of phosphoproteins which previously have shown to improve tryptic digestion and identification of proteolytically resistant proteins compared to standard trypsin digestion23, 24
No significant difference in phosphopeptide identification between two surfactants was observed. There were 125 and 127 unique phosphopeptides corresponding to 90 and 89 phosphoproteins that were identified using NaDOC and urea containing trypsin digestion buffer, respectively. Of these, 73 of 125 (58.4%), and 71 phosphopeptides of 127 identified total phosphopeptides (55.9%) in NaDOC and urea, respectively, were completely digested thereby demonstrating a possibly slightly better efficiency of NaDOC in trypsin digestion. Interestingly, more proteins with positive GRAVY values and with molecular weights higher than 200 were observed in the presence of NaDOC (Table 1). However, there was no significant difference in the average pI obtained using these reagents.
Table 1.
Comparison of statistical parameters of phosphoproteins identified using sodium deoxycholate (NaDOC) or urea in trypsin digestion
| Parameter | Method | |
|---|---|---|
| NaDOCc | Urea | |
| Total identified unique peptides | 125 | 127 |
| Total identified unique proteins | 90 | 89 |
| % of phosphoproteins with positive GRAVYa values | 6.7 | 5.6 |
| % of phosphopeptides with 0 (1) missing cleavage sites | 58.4 (41.6) | 55.9 (44.1) |
| Average pI | 6.75 | 6.70 |
| Molecular weightb < 20 kDa | 5.60% | 8.66% |
| 20 – 40 kDa | 25.60% | 28.35% |
| 40 – 60 kDa | 12.80% | 14.17% |
| 60 – 80 kDa | 12.80% | 10.24% |
| 80–100 kDa | 9.60% | 7.87% |
| 100–120 kDa | 11.20% | 15.75% |
| 120–140 kDa | 5.60% | 4.72% |
| 140–200 kDa | 4.00% | 4.72% |
| > 200 kDa | 12.80% | 5.51% |
GRAVY, Grand Average of Hydropathy value;
Theoretical molecular weight of unique phosphoproteins calculated using ProtParam (http://www.expasy.org/tools/protparam.html) was distributed and compared between two different surfactants containing enzyme digestion;
NaDOC, sodium deoxycholate
Identification of phosphoproteins in LNCaP cells by MS
Enriched phosphopeptides were analyzed by high accuracy MS analysis and the combination of two surfactants: detergent (sodium deoxycholate); and chaotropic reagent (urea) during trypsin digestion. Proteins identified for each group, including peptides identified per protein, protein ID, protein name, protein sequences, charge state, product ion mass were provided in Supplementary Table 1. A total of 746 phosphorylation sites in 540 phosphopeptides were identified in LNCaP cells by phosphopeptide-specific approach using TiO. These 540 phosphopeptides corresponded to 116 unique phosphoproteins of which 56 phosphoproteins have not been previous reported in the phosphoproteome of LNCaP cells (Supplementary Table 2). These data are consistent with previous reports of proliferating LNCaP cells where the phosphor-levels seem relatively low with identification of 81 and 296 phosphoproteins20, 21. Proliferating cells are reported to have a relative abundance of 90% phosphoserine (pS), 10% phosphothreonine (pT), and 0.05% phosphotyrosine (pY)25. Here the distribution of individually identified phosphorylation sites suggested a similar distribution of pS, pT and pY sites that was 88%, 12% and <1%, respectively.
The majority of identified proteins contained one unique peptide hit (Table 2). Most phosphopeptides were singly phosphorylated (72%), but doubly (26%) and triply (2%) phosphorylated peptides were also identified.
Table 2.
Total number of proteins identified per number of unique peptides
Total number of unique phosphoproteins were counted and compared between two different surfactants containing enzyme digestion;
NaDOC, sodium deoxycholate
Classifications of phosphoproteome into biological process, molecular function and cellular component
All identified proteins were categorized according to biological process, molecular function, and cellular component by Gene Ontology (GO) analysis using Discoveryspace26. The total number of proteins identified by LC-MS/MS analysis was found to represent various biological processes (Fig. 2A). The top five biological process categories of phosphoproteins identified in LNCaP cells were: 1) signal transduction (12%); 2) regulation of transcription (12%); 3) mRNA processing (8%); 4) cell differentiation (8%); and 5) RNA splicing (7%).
Fig. 2. Classification of identified phosphoproteins according: (A) to biological process; (B) molecular function; (C) cellular component in NaDOC; and (D) cellular component in urea.
All identified phosphoproteins expressed in LNCaP cells were analyzed and classified in different categories using Gene Ontology (GO). Pie charts represent the most frequent biological functions and processes (A) and molecular function (B) associated with phosphoproteins. Major cellular component of identified phosphoproteins are represented with a slightly different portion of membrane compartments (plasma membrane, ER membrane, and membrane fraction) between the different conditions of digestion, NaDOC (C) and Urea (D).
The identified proteome in LNCaP cells was also classified into molecular functions (Fig. 2B) and revealed that 28% of phosphoproteins were classified to have the molecular function of protein binding, followed by 22% that were involved in nucleic acid binding, 14% with nucleotide binding, and 7% with hydrolase activity.
The cellular localization of phosphoproteins were determined to be localized in cytoplasm (46%) followed by plasma membrane (10%) in the presence of NaDOC or urea. However trypsin digestion with NaDOC led to identification of more membrane proteins than urea (21% and 18% of plasma membrane, ER membrane, and membrane fraction in NaDOC and urea, respectively) (Fig. 2C and 2D)
Signaling pathways and predicted motifs of identified phosphopeptides
Phosphorylation plays an important role in the control of signaling pathways that are dependent on the activities of protein kinases. Signaling pathways involving the identified proteins were categorized and the phosphorylation motifs predicted for the identification of targets of phosphorylation using PANTHER (http://www.pantherdb.org/) which uses a large collection of 6,683 protein families that cover 90% of mammalian protein-coding genes27 and categorizes identified genes into signaling pathways. Proteins involving Wnt signaling pathway represented the largest group of 35 different signaling pathways. Proteins involved in cadherin signaling pathway represented the second largest group. Other pathways included Rho GTPase, heterotrimeric G-protein signaling, Gi alpha and Gs alpha mediated pathway, and Alzheimer disease-presenilin pathway (Fig. 3).
Fig. 3. Signaling pathways involving identified phosphoproteins.
Different signaling pathways hits are represented by PANTHER analysis from all identified phosphoproteins in LNCaP cells. The major signaling pathway was Wnt, followed by cadherin, Rho GTPase, heterotrimeric G-protein and Gi alpha and Gs alpha mediated signaling pathways.
To identify potential common phosphorylation motifs, PHOSIDA was employed. This is an algorithm/ database designed to extract motifs from large sets of naturally occurring phosphorylation sites. A query of our dataset for phosphopeptides was predicted to have 20 different motifs and the majority of identified phosphopeptides was demonstrated to have motifs for casein kinase (CK) 1 and 2 followed by GSK3 (Table 3).
Table 3.
Distribution of predicted kinase motifs of identified phosphopeptides
| Kinase | % | Kinase | % |
|---|---|---|---|
| CK1 | 28.14% | Aurora | 1.71% |
| CK2 | 22.60% | EGFR | 1.71% |
| GSK3 | 9.59% | SRC | 1.28% |
| CAM2K | 8.32% | AKT | 0.64% |
| NEK6 | 7.68% | ALK | 0.64% |
| PKA | 5.12% | ABL | 0.21% |
| ERK | 3.20% | Aurora-A | 0.21% |
| CDK1 | 2.99% | CHK1 | 0.21% |
| PLK1 | 2.99% | PKD | 0.21% |
| CDK2 | 2.35% | PLK | 0.21% |
Androgen receptor and its interacting proteins
AR is suspected to be important in all stages of prostate cancer. Although AR is a phosphoprotein, it was not detected here with either approach. The inability to detect phosphoAR is possibly due to low expression level and/or the requirement to use a combination of trypsin and Glu-C digestion to obtain optimally-sized cleavage products for MS analysis. Approximately 170 proteins that are involved in a variety of processes have been reported to interact with the AR28. Here we identified 3 proteins which are known to interact with AR as a phosphorylated form (Table 4). These proteins were histone deacetylase 2 (HDAC2) (Fig. 4A), ubiquitin carboxyl-terminal hydrolase 10 (USP10) (Fig. 4B) and β-catenin (CTNNB1) (Fig. 4C). Data from MS analysis including phosphorylation sites identified by Mascot are shown in Table 5. These sites correspond to casein kinase-2 motif (S/T-X-X-E) in serine 8 and 10 of HDAC2 and in serine 16 of USP10 as well as PKA motif (R-X-S/T) in serine 3 of CTNNB1.
Table 4.
Identified proteins known to interact with AR as phosphorylated forms
| Protein Acc. No.a |
Protein Name | Gene Name |
Functionsb | coA/ coRc |
Refd |
|---|---|---|---|---|---|
| IPI00289601 | Histone deacetylase 2 | HDAC2 | Deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Transcriptional regulation, cell cycle progression and developmental events. Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. Interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, CAF1. |
coR | 54, 76 |
| IPI00291946 | Ubiquitin carboxyl-terminal hydrolase 10 | USP10 | Ubiquitin specific protease are required to remove ubiquitin from specific proteins or peptides to which ubiquitin is attached. | coA | 57 |
| IPI00017292 | Isoform 1 of Catenin beta-1 | CTNNB1 | Regulation of cell adhesion and signal transduction through the Wnt pathway. | coA | 56, 77–79 |
Protein Acc. No., Protein accession number searched in IPI_human database;
Functions, molecular functions of proteins referred in SwisProt;
coA/ coR, Co-activator and Co-repressor in androgen receptor (AR) signaling;
Ref, References described about proteins
Fig. 4. MS/MS spectrum of phosphopeptides of AR-interacting proteins.
Representative MS/MS spectrum of phosphopeptides identified for HDAC2, USP10, and β-catenin and the protein kinase motif of each peptide predicted using PHOSIDA. MS/MS of the precursor ion of m/z 773.2621(2+) of HDAC2, confirming the indicated peptide sequence, IACDEEFpSDpSEDEGEGGRR with predicted CK2 motif (A), m/z 1036.4176 (2+) of USP10, confirming the indicated peptide sequence, NHSVNEEEQEEQGEGpSEDEWEQVGPR with predicted CK2 motif (B) and m/z 620.9515 (2+) of β-catenin, confirming the indicated peptide sequence, RTpSMGGRQQQFVEGVR with predicted PKA motif (C).
Table 5.
Data from mass spectrometry analysis including phosphorylation sites and physical parameters of identified phosphorylated AR interacting proteins
| Acc. No.a | Protein Name | AAb | Mwc (kDa) |
pId | GRAVYe | Surfactants | Pep_scoref | miss | Peptide sequenceg | P-sitesh |
|---|---|---|---|---|---|---|---|---|---|---|
| IPI00289601 | Histone deacetylase 2 | 488 | 55.36 | 5.59 | −0.718 | Urea | 52.76 | 1 | R.IACDEEFSDSEDEGEGGRR.N | S422, S424 |
| IPI00291946 | Ubiquitin carboxyl-terminal hydrolase 10 | 798 | 87.13 | 5.19 | −0.449 | Urea NaDOC |
111.35 80.02 |
0 0 |
K.NHSVNEEEQEEQGEGSEDEWEQVGPR.N K.NHSVNEEEQEEQGEGSEDEWEQVGPR.N |
S576 S576 |
| IPI00017292 | Isoform 1 of Catenin beta-1 | 781 | 85.49 | 5.53 | −0.175 | Urea NaDOC NaDOC |
66.32 80.26 129.00 |
1 0 0 |
R.RTSMGGTQQQFVEGVR.M R.TSMGGTQQQFVEGVR.M R.TSMGGTQQQFVEGVR.M |
S552 T551 S552 |
Acc. No., Protein accession number searched in IPI_human database;
AA, The number of amino acid of protein;
Mw, Theoretical molecular weight;
pI, Theoretical isoelectric point;
GRAVY, Grand Average of Hydropathy value;
pep_score, Peptide score acquired from Mascot search;
Peptide sequence, Identified phosphopeptide sequences (the modification of phosphorylation on serine and threonine residue as well as oxidation on methionine residue were underlined);
P-sites, The position of phosphorylation sites in protein sequence
Mapping a network of identified cancer-related molecules and molecules involved in prostate cancer
The association of the cancer-related molecules among identified phosphoproteins and the relationships to prostate cancer was mapped using Ingenuity Pathways Analysis (IPA) (Fig. 5). A total of 61 molecules were observed to be involved in the networks related with cancer function directly or indirectly. Molecules identified as phosphorylated forms that play important roles in prostate cancer were splicing factor 1 (SF1), regulator of cohesion maintenance homolog B (PDS5B), nucleolin (NCL), β-catenin (CTNNB1), histone deacetylase 2 (HDAC2), and minichromosome maintenance complex component 2 (MCM2). All phosphorylation sites of these proteins were previously identified in a large scale phosphoproteome analysis in HeLa cells and HEK293 cells29–31, but the role of phosphorylation and phosphorylation-induced molecular actions have not been reported. Dysregulation of these molecules may give rise to initiation and progression of cancer and provide potential targets for therapeutic intervention.
Fig. 5. Ingenuity pathway analysis of cancer related phosphoproteins.
Sixty-one genes reported in the relationship with cancer are represented from all identified phosphoproteins in LNCaP cells. Interactions, localization and prostate cancer function are shown. Direct and indirect involvement in cancer represented in blue and gray lines, respectively.
Discussion
Analysis of the phosphoproteome of cells can provide a detailed view of signaling pathways and elucidate potential targets for rational drug development. The phosphoproteome has been analyzed in numerous cancer cell lines including human leukemic monocyte lymphoma U937 cells32, human colon adenocarcinoma HT-29 cells33, B lymphoma WEHI-231 cells34, Hela cervical cancer cells35 and lung adenoma carcinoma A549 cells36.
In an effort to identify phosphoproteins and signaling pathways in prostate cancer, we employed the MS analysis combined with highly selective TiO2 phosphopeptide enrichment method using LNCaP cells as a model for prostate cancer. Both NaDOC and urea were used during enzyme digestion to maximize the identification of phosphoproteins. It is necessary to consider the compatibility of reagent with MS as it can interfere with analysis by obscuring and/or suppressing the signal, formation of adducts, and shift the charge states. Extensive work has been done to evaluate the compatibility of a variety of surfactants on MS37 and urea and NaDOC are generally accepted. Urea is a commonly used chaotropic reagent to denature proteins as it is easily removed by reverse-phase liquid chromatography. NaDOC is a detergent that is compatible with MS and can be used at high concentrations to improve trypsin digestion and identification of proteins38, 39. The combination of two different surfactants for trypsin digestion showed slightly increased identification efficiency of phosphoproteins. Phosphoproteome analysis with NaDOC containing enzyme digestion demonstrated slightly increased identification of phosphopeptides and hydrophobic proteins, as well as improved efficiency of trypsin digestion. Importantly here we identified a total of 116 phosphoproteins of which 56 had not been previously reported in LNCaP cells. Of 116 phosphoproteins, 28 and 27 proteins uniquely identified by urea and NaDOC buffer, respectively. Technical steps to improve analysis of phosphoproteome become paramount in cell lines or samples where the phosphor-levels are relatively low during regular growth of cells or in the absence of stimulation with growth factors.
Analysis of the phosphorylation motifs on the identified proteins yielded an abundance of sites for the serine/threonine specific protein kinase family, CK1 and CK2, as well as glycogen synthase kinase 3 (GSK-3). CK1 is ubiquitously expressed in eukaryotic organisms and mediates the phosphorylation of many substrates that are involved in various cellular processes including cell differentiation, proliferation, membrane transport, and oncogenesis. CK2 is implicated in cell growth and can affect prostate cancer development40, 41. Inhibition of CK2 activity decreases AR protein and AR-dependent transcription42. GSK-3 is widely expressed in mammalian tissues and phosphorylates members of the steroid receptor family43–45, including AR, but its effects on AR transcriptional activity remain controversial43, 46–48. Phosphoproteins identified with motifs for GSK3 was MAP1B49 and for CK2 were SSB50, IGF2R51 and YBX152.
There is increasing evidence that hormonal progression of prostate cancer is mediated through aberrant activity of the AR by overexpression of the AR and/or altered interactions with AR coregulators such as coactivators and corepressors. Here we identified phosphorylated USP10, HDAC2, and β-catenin, which interact with AR. The phosphorylation sites identified are novel hence no functional studies have been reported that characterize these sites.
HDACs influence differentiation, and proliferation of cancer cells. HDAC2 is suggested to be an independent prognostic marker for prostate cancer patients and is associated with biochemical failure and recurrence53. Phosphorylation of HDAC2 by CK2 on ser394 and potentially ser411, ser422, and ser424 is known to promote enzymatic activity and regulates complex formation, but has no effect on transcriptional repression54. We identified ser422 and ser424 phosphorylation sites of HDAC2 that lie within CK2 recognition sequences.
β-catenin is a multifunctional molecule that plays important roles in cell-cell adhesion and Wnt signal transduction. In the absence of Wnt signaling, protein levels of β-catenin are regulated by phosphorylation on its NH2-terminal region by GSK3 which leads to its ubiquitination and degradation. Wnt signaling inhibits this process to cause accumulation of β-catenin such that it can translocate to the nucleus and modify the activity of Tcf/Lef transcription factors55. β-catenin is an important coactivator of the AR and thought to be a major player in prostate cancer56. Here we identified phosphorylated β-catenin which was consistent with a previous study using this cell line20.
USP10 is an ubiquitin-specific protease that we identified as a phosphoprotein in LNCaP cells. The biological role of USP10 is not fully understood, but it is known to interact with DNA-bound AR complexes57. USP10 has been detected as a phosphoprotein in Hela cells35, 58, HEK293 cells59, human embryonic kidney 293T cells60, and consistent with our data, also in LNCaP cells20. Physical interaction between USP10 and G3BP, a RasGAP interacting protein overexpressed in tumors, was shown by a two-hybrid screen to suggest a link between the ubiquitination pathway and Ras-mediated signaling61
More than half of the identified phosphoproteins were mapped to relate with cancer function. These phosphoproteins include, splicing factor 1 (SF1)62, sister chromatid cohesion protein PDS5 homolog B (PDS5B)63, 64, nucleolin (NCL)65, β-catenin66, 67, histone deacetylase 2 (HDAC2)68, and DNA replication licensing factor MCM2 (MCM2)69 and were linked into prostate cancer disease using IPA analysis. Phosphorylation of MCM2 is involved in the initiation of DNA replication in Hela cells70. Elucidation of the role of phosphorylation of these molecules may provide insight into the molecular mechanisms underlying prostate cancer.
Materials and Methods
Cell Culture
LNCaP human prostate cancer cells (L.W.K. Chung, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center) were maintained in phenol red-free RPMI 1640 culture medium (Stem Cell Technology, Vancouver, BC) supplemented with 5% fetal bovine serum (FBS) (Hyclone, Logan, UT), 100units/mL penicillin and 100ug/uL streptomycin (Stem cell technology). All other chemicals were from Sigma-Aldrich (Oakville, ON) unless stated.
Sample Preparation
LNCaP cells which have approximately 36 hours-doubling time were harvested in log-phase growth (approximately 80% confluent). Protein lysates were prepared by tissue homogenizing using 1% Nonidet P-40, 10 mM Tris-HCl (pH 7.4), 50 mM NaCl, 5 mM NaF, 5 mM Na3VO4, 10 mM beta-glycerophosphate, and complete-mini EDTA free protease inhibitor cocktail tablets (Roche Applied Science, Laval, Quebec). Nucleic acids were degraded using benzonase (Novagen, Mississauga, ON) and lysates were clarified by centrifugation at 20,000 × g for 10 min at 4°C. Protein concentrations were determined using a bicinchoninic acid protein assay (BioRad, Hercules, CA).
Trypsin digestion
Proteins from two aliquots of LNCaP lysate were precipitated for 16 hours at −20°C with 9 volumes of ice-cold acetone. Protein pellets were collected by centrifugation at 20,000 × g for 30 min at 4°C. Proteins were resolubilized using either 8 M urea or 1% sodium deoxycholate (NaDOC). Samples were reduced with dithiothreitol and alkylated with iodoacetamide prior to dilution with 50 mM ammonium bicarbonate (pH 8.0) to reduce concentration of urea to level compatible with trypsin activity (<1 M). Trypsin (sequencing grade) (Promega, Madison, WI, USA) was added at a 50:1 substrate:enzyme ratio and digestion was conducted for 16 hours at 37°C. Trypsin digestion was stopped with the addition of formic acid to a final concentration of 1%. NaDOC is insoluble below pH 2.0 and was removed by centrifugation for 5 min at 20,000 × g at room temperature.
Enrichment of phosphopeptides
Phosphorylation is often substoichiometric thereby necessitating an affinity enrichment procedure prior to analysis and detection by MS. Here we use titanium dioxide (TiO2) affinity method that is highly selective for phosphorylated peptides71. Prior to TiO2 binding, digested peptides were desalted using reversed phase solid phase extraction with Waters Oasis HLB cartridges. Peptides were eluted from the HLB columns using 500 µL of TiO2 binding buffer (80% acetonitrile, 0.1% trifluoroacetic acid (TFA), 300 mg/mL dihydroxybenzoic acid (DHB))72. TiO2 binding buffer was added to TiO2 beads (GL Sciences, Japan) to create 50% slurry. TiO2 microcolumns and phosphopeptide enrichment was conducted as described71.
Briefly, TiO2 bead slurry was added to each desalted LNCaP digest and incubation was conducted at room temperature for 30 min. TiO2 bead slurries were transferred to individual fitted microcolumns. TiO2 beads were washed with TiO2 binding buffer, followed by wash buffer (80% acetonitrile, 0.1% TFA). Bound peptides were eluted with 20 µL of ammonium hydroxide and eluted samples were acidified with an equal volume of 10% formic acid.
Mass spectrometry analysis
Analysis of peptides was conducted using an LC Packings Famos Autosampler with an LC Packings Ultimate nanoflow HPLC coupled to a nano-electrospray ionization source on a QSTAR Pulsar I (Applied Biosystems, Streetsville, Ontario). The HPLC was operated with a desalting column (0.3 × 5 mm) HPLC plumbing configuration to protect the analytical column (Magic C18 resin, 150 mm × 75 µm inner diameter). Samples were loaded onto the desalting column at 50 µL/min with 100% solvent A (2% v/v acetonitrile, 0.1% formic acid) for 5 min. Upon switching the desalting column in-line with the analytical column, a 300 nL/min gradient was used as follows: 60 min linear gradient from 0–20% solvent B (98% v/v acetonitrile, 0.1% formic acid); 30 min linear gradient from 20–40% solvent B; 12 min linear gradient from 40–80% solvent B.
Tandem MS spectra were acquired in a data dependent fashion selecting the top 2 most intense eluting ions in the 400–1200 m/z range with a 2+ to 5+ charge state. Following MS/MS analysis, each precursor ion was excluded from selection for further MS/MS analysis for 180 s. Raw MS/MS data was centroided, deisotoped and converted to peak lists using mascot.dll (version 1.6b23, Matrix Science, London, UK) for Analyst QS 1.1. Peak lists were queried against the Human IPI database version 3.43 (72,350 sequences) using Mascot 2.2 (Matrix Science). Search parameters included trypsin enzyme specificity with 1 missed cleavage permitted, and 0.3 Da and 0.1 Da precursor and fragment ion mass error, respectively. Carbamidomethylation of Cys was allowed for fixed modifications and deamidation of Gln and Asn, oxidation of Met, and phosphorylation of Ser, Thr and Tyr were allowed as variable modifications.
Computational analysis
All identified phosphoproteins were categorized according to signaling pathways, biological process, cellular component and molecular function using PANTHER (http://www.pantherdb.org/) (version 4.01)27 and Discoveryspace (version 2.1)26 for the identification of targets of reversible phosphorylation. PHOSIDA (http://www.phosida.com) was used to predict phosphorylation motifs involved. PHOSIDA is designed to extract motifs from large sets of naturally occurring phosphorylation sites matching kinase motifs, predicted secondary structures, conservation patterns, and its dynamic regulation upon stimulus73. bioDBnet (http://biodbnet.abcc.ncifcrf.gov/db/db2db.php)74 was used to convert UniProt ID to IPI to compare proteins identified in our study with in other two studies20, 21.
Ingenuity Pathways Analysis (IPA) (version 6.3) aids in identifying interactions and functions of gene products using information based on the literatures. IPA was used to map the connection of identified and cancer related gene products as well as their involvements of signaling pathways (http://www.ingenuity.com/).
Molecular weights, theoretical isoelectric point (pI) and Grand Average of Hydropathy (GRAVY) value were calculated using ProtParam (http://www.expasy.org/tools/protparam.html) for each protein. The GRAVY value for a peptide or protein was calculated as the sum of hydropathy values of all the amino acids, divided by the number of residues in the sequence and shows the hydrophobicity of proteins75.
Conclusion
In conclusion, the application of detergent and chaotropes with enzyme digestion followed by a phosphopeptide enrichment strategy yielded identification of 116 phosphopeptides, of which 56 have not been reported previously in LNCaP human prostate cancer cells. Identification of the phosphoproteome reveals valuable biological functions as well as the network of signaling pathways that may be important in prostate cancer. Novel phosphorylation sites of β-catenin, HDAC2, and USP10 which are known to interact with AR and other cancer-related molecules could be further characterized to elucidate molecular mechanism involved in prostate cancer.
Supplementary Material
Acknowledgments
The authors thank Country Meadows Senior Men’s Golf Charity and FORE P.A.R. Charity Golf Classic for generous donations to purchase essential equipment. This work was supported by the Canadian Institutes of Health Research (CIHR, grant number MOP 79308) and National Cancer Institute/National Institutes of Health (2R01-CA105304).
Abbreviations
- AR
Androgen Receptor
- CK
Casein Kinase
- GO
Gene Ontology
- GSK-3
Glycogen Synthase Kinase 3
- HDAC
Histone Deacetylase
- HPLC
High Performance Liquid Chromatography
- MS
Mass Spectrometry
- MudPIT
Multidimensional Protein Identification Technology
- MW
Molecular Weight
- NaDOC
Sodium Deoxycholate
- pS
Phosphoserine
- PSA
Prostate-Specific Antigen
- pT
Phosphothreonine
- PTM
Post-translational Modification
- pY
Phosphotyrosine
- SILAC
Stable Isotope Labeling with Amino Acids in Cell Culture
References
- 1.Sadar MD. J. Biol. Chem. 1999;274:7777–7783. doi: 10.1074/jbc.274.12.7777. [DOI] [PubMed] [Google Scholar]
- 2.Ueda T, Mawji NR, Bruchovsky N, Sadar MD. J. Biol. Chem. 2002;277:38087–38094. doi: 10.1074/jbc.M203313200. [DOI] [PubMed] [Google Scholar]
- 3.Gioeli D. Clin. Sci. (Lond) 2005;108:293–308. doi: 10.1042/CS20040329. [DOI] [PubMed] [Google Scholar]
- 4.Scher HI, Sawyers CL. J. Clin. Oncol. 2005;23:8253–8261. doi: 10.1200/JCO.2005.03.4777. [DOI] [PubMed] [Google Scholar]
- 5.Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Cancer. Cell. 2011;19:575–586. doi: 10.1016/j.ccr.2011.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Edwards J. Expert Opin. Investig. Drugs. 2010;19:605–614. doi: 10.1517/13543781003789388. [DOI] [PubMed] [Google Scholar]
- 7.Sadar MD. In: Tindall DJ, Mohler JL, editors. Springer Publishers; 2009. pp. 465–506. [Google Scholar]
- 8.Hubbard MJ, Cohen P. Trends Biochem. Sci. 1993;18:172–177. doi: 10.1016/0968-0004(93)90109-z. [DOI] [PubMed] [Google Scholar]
- 9.Aebersold R, Mann M. Nature. 2003;422:198–207. doi: 10.1038/nature01511. [DOI] [PubMed] [Google Scholar]
- 10.Salomon AR, Ficarro SB, Brill LM, Brinker A, Phung QT, Ericson C, Sauer K, Brock A, Horn DM, Schultz PG, Peters EC. Proc. Natl. Acad. Sci. U. S. A. 2003;100:443–448. doi: 10.1073/pnas.2436191100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Clin. Chem. 2005;51:695–707. doi: 10.1373/clinchem.2004.041087. [DOI] [PubMed] [Google Scholar]
- 12.Everley PA, Krijgsveld J, Zetter BR, Gygi SP. Mol. Cell. Proteomics. 2004;3:729–735. doi: 10.1074/mcp.M400021-MCP200. [DOI] [PubMed] [Google Scholar]
- 13.Comuzzi B, Sadar MD. Cellscience. 2006;3:61–81. doi: 10.1901/jaba.2006.3-61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Zhou ZX, Kemppainen JA, Wilson EM. Mol. Endocrinol. 1995;9:605–615. doi: 10.1210/mend.9.5.7565807. [DOI] [PubMed] [Google Scholar]
- 15.Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. J. Biol. Chem. 2002;277:29304–29314. doi: 10.1074/jbc.M204131200. [DOI] [PubMed] [Google Scholar]
- 16.Nazareth LV, Weigel NL. J. Biol. Chem. 1996;271:19900–19907. doi: 10.1074/jbc.271.33.19900. [DOI] [PubMed] [Google Scholar]
- 17.Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Oncogene. 2010;29:3208–3216. doi: 10.1038/onc.2010.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC, Conaway M, Carey MF, Gioeli D. Mol. Endocrinol. 2010;24:2267–2280. doi: 10.1210/me.2010-0238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Cobb LJ, Mehta H, Cohen P. Mol. Endocrinol. 2009;23:1624–1633. doi: 10.1210/me.2008-0365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Giorgianni F, Zhao Y, Desiderio DM, Beranova-Giorgianni S. Electrophoresis. 2007;28:2027–2034. doi: 10.1002/elps.200600782. [DOI] [PubMed] [Google Scholar]
- 21.Chen L, Giorgianni F, Beranova-Giorgianni S. J. Proteome Res. 2010;9:174–178. doi: 10.1021/pr900338q. [DOI] [PubMed] [Google Scholar]
- 22.Jensen SS, Larsen MR. Rapid Commun. Mass Spectrom. 2007;21:3635–3645. doi: 10.1002/rcm.3254. [DOI] [PubMed] [Google Scholar]
- 23.Lin Y, Zhou J, Bi D, Chen P, Wang X, Liang S. Anal. Biochem. 2008;377:259–266. doi: 10.1016/j.ab.2008.03.009. [DOI] [PubMed] [Google Scholar]
- 24.Chen EI, Cociorva D, Norris JL, Yates JR., 3rd J. Proteome Res. 2007;6:2529–2538. doi: 10.1021/pr060682a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Hunter T, Sefton BM. Proc. Natl. Acad. Sci. U. S. A. 1980;77:1311–1315. doi: 10.1073/pnas.77.3.1311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Robertson N, Oveisi-Fordorei M, Zuyderduyn SD, Varhol RJ, Fjell C, Marra M, Jones S, Siddiqui A. Genome Biol. 2007;8:R6. doi: 10.1186/gb-2007-8-1-r6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Mi H, Guo N, Kejariwal A, Thomas PD. Nucleic Acids Res. 2007;35:D247–D252. doi: 10.1093/nar/gkl869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Heemers HV, Tindall DJ. Endocr. Rev. 2007;28:778–808. doi: 10.1210/er.2007-0019. [DOI] [PubMed] [Google Scholar]
- 29.Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M. Cell. 2006;127:635–648. doi: 10.1016/j.cell.2006.09.026. [DOI] [PubMed] [Google Scholar]
- 30.Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Anal. Chem. 2009;81:4493–4501. doi: 10.1021/ac9004309. [DOI] [PubMed] [Google Scholar]
- 31.Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP. Proc. Natl. Acad. Sci. U. S. A. 2008;105:10762–10767. doi: 10.1073/pnas.0805139105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Metodiev MV, Timanova A, Stone DE. Proteomics. 2004;4:1433–1438. doi: 10.1002/pmic.200300683. [DOI] [PubMed] [Google Scholar]
- 33.Kim JE, Tannenbaum SR, White FM. J. Proteome Res. 2005;4:1339–1346. doi: 10.1021/pr050048h. [DOI] [PubMed] [Google Scholar]
- 34.Shu H, Chen S, Bi Q, Mumby M, Brekken DL. Mol. Cell. Proteomics. 2004;3:279–286. doi: 10.1074/mcp.D300003-MCP200. [DOI] [PubMed] [Google Scholar]
- 35.Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M. Cell. 2006;127:635–648. doi: 10.1016/j.cell.2006.09.026. [DOI] [PubMed] [Google Scholar]
- 36.Yu G, Xiao CL, Lu CH, Jia HT, Ge F, Wang W, Yin XF, Jia HL, He JX, He QY. Mol. Biosyst. 2011;7:472–479. doi: 10.1039/c0mb00055h. [DOI] [PubMed] [Google Scholar]
- 37.Kim SC, Chen Y, Mirza S, Xu Y, Lee J, Liu P, Zhao Y. J. Proteome Res. 2006;5:3446–3452. doi: 10.1021/pr0603396. [DOI] [PubMed] [Google Scholar]
- 38.Zhou J, Zhou T, Cao R, Liu Z, Shen J, Chen P, Wang X, Liang S. J. Proteome Res. 2006;5:2547–2553. doi: 10.1021/pr060112a. [DOI] [PubMed] [Google Scholar]
- 39.Lin Y, Zhou J, Bi D, Chen P, Wang X, Liang S. Anal. Biochem. 2008;377:259–266. doi: 10.1016/j.ab.2008.03.009. [DOI] [PubMed] [Google Scholar]
- 40.Hessenauer A, Montenarh M, Gotz C. Int. J. Oncol. 2003;22:1263–1270. [PubMed] [Google Scholar]
- 41.Guo C, Yu S, Davis AT, Ahmed K. Cancer Res. 1999;59:1146–1151. [PubMed] [Google Scholar]
- 42.Gotz C, Bachmann C, Montenarh M. Prostate. 2007;67:125–134. doi: 10.1002/pros.20471. [DOI] [PubMed] [Google Scholar]
- 43.Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. J. Biol. Chem. 2004;279:19191–19200. doi: 10.1074/jbc.M309560200. [DOI] [PubMed] [Google Scholar]
- 44.Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. J. Biol. Chem. 2005;280:33006–33014. doi: 10.1074/jbc.M506758200. [DOI] [PubMed] [Google Scholar]
- 45.Rogatsky I, Waase CL, Garabedian MJ. J. Biol. Chem. 1998;273:14315–14321. doi: 10.1074/jbc.273.23.14315. [DOI] [PubMed] [Google Scholar]
- 46.Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Oncogene. 2004;23:7882–7892. doi: 10.1038/sj.onc.1208068. [DOI] [PubMed] [Google Scholar]
- 47.Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Endocrinology. 2004;145:2941–2949. doi: 10.1210/en.2003-1519. [DOI] [PubMed] [Google Scholar]
- 48.Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. J. Biol. Chem. 2004;279:32444–32452. doi: 10.1074/jbc.M313963200. [DOI] [PubMed] [Google Scholar]
- 49.Scales TM, Lin S, Kraus M, Goold RG, Gordon-Weeks PR. J. Cell. Sci. 2009;122:2424–2435. doi: 10.1242/jcs.040162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Fan H, Sakulich AL, Goodier JL, Zhang X, Qin J, Maraia RJ. Cell. 1997;88:707–715. doi: 10.1016/s0092-8674(00)81913-3. [DOI] [PubMed] [Google Scholar]
- 51.Meresse S, Ludwig T, Frank R, Hoflack B. J. Biol. Chem. 1990;265:18833–18842. [PubMed] [Google Scholar]
- 52.Scott GK, Fei H, Thomas L, Medigeshi GR, Thomas G. EMBO J. 2006;25:4423–4435. doi: 10.1038/sj.emboj.7601336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G. Br. J. Cancer. 2008;98:604–610. doi: 10.1038/sj.bjc.6604199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Tsai SC, Seto E. J. Biol. Chem. 2002;277:31826–31833. doi: 10.1074/jbc.M204149200. [DOI] [PubMed] [Google Scholar]
- 55.van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. J. Biol. Chem. 2002;277:17901–17905. doi: 10.1074/jbc.M111635200. [DOI] [PubMed] [Google Scholar]
- 56.Yardy GW, Brewster SF. Prostate Cancer. Prostatic Dis. 2005;8:119–126. doi: 10.1038/sj.pcan.4500794. [DOI] [PubMed] [Google Scholar]
- 57.Faus H, Meyer HA, Huber M, Bahr I, Haendler B. Mol. Cell. Endocrinol. 2005;245:138–146. doi: 10.1016/j.mce.2005.11.011. [DOI] [PubMed] [Google Scholar]
- 58.Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen J, Li J, Cohn MA, Cantley LC, Gygi SP. Proc. Natl. Acad. Sci. U. S. A. 2004;101:12130–12135. doi: 10.1073/pnas.0404720101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Tang LY, Deng N, Wang LS, Dai J, Wang ZL, Jiang XS, Li SJ, Li L, Sheng QH, Wu DQ, Li L, Zeng R. Mol. Cell. Proteomics. 2007;6:1952–1967. doi: 10.1074/mcp.M700120-MCP200. [DOI] [PubMed] [Google Scholar]
- 60.Molina H, Horn DM, Tang N, Mathivanan S, Pandey A. Proc. Natl. Acad. Sci. U. S. A. 2007;104:2199–2204. doi: 10.1073/pnas.0611217104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Soncini C, Berdo I, Draetta G. Oncogene. 2001;20:3869–3879. doi: 10.1038/sj.onc.1204553. [DOI] [PubMed] [Google Scholar]
- 62.Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Cancer Res. 2008;68:927–936. doi: 10.1158/0008-5472.CAN-07-2608. [DOI] [PubMed] [Google Scholar]
- 63.Geck P, Maffini MV, Szelei J, Sonnenschein C, Soto AM. Proc. Natl. Acad. Sci. U. S. A. 2000;97:10185–10190. doi: 10.1073/pnas.97.18.10185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Maffini MV, Geck P, Powell CE, Sonnenschein C, Soto AM. Endocrinology. 2002;143:2708–2714. doi: 10.1210/endo.143.7.8899. [DOI] [PubMed] [Google Scholar]
- 65.Reyes-Reyes EM, Teng Y, Bates PJ. Cancer Res. 2010;70:8617–8629. doi: 10.1158/0008-5472.CAN-10-0920. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Miller JR, Hocking AM, Brown JD, Moon RT. Oncogene. 1999;18:7860–7872. doi: 10.1038/sj.onc.1203245. [DOI] [PubMed] [Google Scholar]
- 67.Farina AK, Bong YS, Feltes CM, Byers SW. PLoS One. 2009;4:e4797. doi: 10.1371/journal.pone.0004797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Proc. Natl. Acad. Sci. U. S. A. 2010;107:14639–14644. doi: 10.1073/pnas.1008522107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Han YC, Yu YP, Nelson J, Wu C, Wang H, Michalopoulos GK, Luo JH. Cancer Res. 2010;70:4375–4384. doi: 10.1158/0008-5472.CAN-09-4403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Tsuji T, Ficarro SB, Jiang W. Mol. Biol. Cell. 2006;17:4459–4472. doi: 10.1091/mbc.E06-03-0241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Thingholm TE, Jorgensen TJ, Jensen ON, Larsen MR. Nat. Protoc. 2006;1:1929–1935. doi: 10.1038/nprot.2006.185. [DOI] [PubMed] [Google Scholar]
- 72.Larsen MR, Thingholm TE, Jensen ON, Roepstorff P, Jorgensen TJ. Mol. Cell. Proteomics. 2005;4:873–886. doi: 10.1074/mcp.T500007-MCP200. [DOI] [PubMed] [Google Scholar]
- 73.Gnad F, Ren S, Cox J, Olsen JV, Macek B, Oroshi M, Mann M. Genome Biol. 2007;8:R250. doi: 10.1186/gb-2007-8-11-r250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Mudunuri U, Che A, Yi M, Stephens RM. Bioinformatics. 2009;25:555–556. doi: 10.1093/bioinformatics/btn654. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Kyte J, Doolittle RF. J. Mol. Biol. 1982;157:105–132. doi: 10.1016/0022-2836(82)90515-0. [DOI] [PubMed] [Google Scholar]
- 76.Pluemsampant S, Safronova OS, Nakahama K, Morita I. Int. J. Cancer. 2008;122:333–341. doi: 10.1002/ijc.23094. [DOI] [PubMed] [Google Scholar]
- 77.Vlad A, Rohrs S, Klein-Hitpass L, Muller O. Cell. Signal. 2008;20:795–802. doi: 10.1016/j.cellsig.2007.10.031. [DOI] [PubMed] [Google Scholar]
- 78.Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM. Cancer Res. 2004;64:7918–7926. doi: 10.1158/0008-5472.CAN-04-2704. [DOI] [PubMed] [Google Scholar]
- 79.Robinson DR, Zylstra CR, Williams BO. Curr. Drug Targets. 2008;9:571–580. doi: 10.2174/138945008784911831. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.





